| Trial name or title |
IntraCerebral Hemorrahge Acutely Decreasing Arterial Pressure Trial |
| Methods |
Multicentre, randomised, open label, blinded endpoint trial |
| Participants |
Patients who have acute ICH, confirmed by CT diagnosis |
| Interventions |
10 mg iv bolus of labetalol or control |
| Outcomes |
Primary outcome: imaging marker (peri‐hematomal rCBF, as measured with CT perfusion 2 hours after anti‐hypertensive therapy is initiated) |
| Starting date |
2007 |
| Contact information |
Ken Butcher, Division of Neurology, 2E3.13 Walter C Mackenzie Health Sciences Centre, 8440 112 St, Edmonton, Alberta, T6G 2B7, Canada |
| Notes |
Funding: University of Alberta University Hospital Foundation |
